Opioid Stewardship in the Inpatient Ward: Lessons from HM17

Opioids remain essential in acute care, yet every inpatient prescription carries a balance between relief, function, adverse effects and future risk. Hospitalists must treat severe pain promptly while avoiding avoidable exposure, medication errors, oversedation and poorly coordinated discharge plans. The practical focus is stewardship: choosing the right medicine, dose, route and duration for the individual patient.

The education associated with Hospital Medicine 2017 placed evidence-based prescribing, patient safety, clinical decision-making and interdisciplinary practice at the centre of hospital medicine. Its learning resources remain useful for translating broad principles into ward routines, and the HM17 conference resources provide historical context for the approaches discussed by hospitalists and other healthcare professionals.

Australian hospitals apply these principles within a distinct system. A patient may move between a metropolitan emergency department in Melbourne, a surgical ward in Perth and a rural general practice with limited access to specialist pain services. State and territory medicines legislation, Therapeutic Goods Administration requirements, Pharmaceutical Benefits Scheme arrangements and local formulary rules all shape what can be prescribed and supplied. Stewardship therefore needs to be clinically sound, operationally realistic and clear at every handover.

Start With A Structured Pain Assessment

Pain scores are useful, but they should not be the sole reason for escalating an opioid. A bedside assessment should distinguish acute nociceptive pain, neuropathic features, inflammatory pain, opioid tolerance, opioid withdrawal and pain associated with anxiety or sleep disruption. Ask what the patient can currently do, what movement is limited, and what outcome matters over the next several hours.

The medication history deserves equal attention. Confirm prescribed medicines, over-the-counter products, recent emergency presentations, opioid substitution treatment and medicines obtained from more than one pharmacy. In Australia, the patient’s My Health Record may provide useful information, while state-based prescription monitoring systems can support safer decisions where available. A conversation about cannabis, alcohol, sedatives and non-prescribed opioids should be routine and non-judgemental.

Before prescribing, identify factors that increase harm: obstructive sleep apnoea, chronic respiratory disease, renal or hepatic impairment, frailty, delirium, pregnancy and concurrent benzodiazepine use. Document the working pain diagnosis, functional target and review time. “Pain relief” is too vague; “walk to the bathroom with physiotherapy this afternoon” gives the team a measurable clinical goal.

Prefer Multimodal Analgesia

An opioid should usually be one component of a multimodal analgesic plan rather than the complete plan. Depending on the diagnosis, this can include paracetamol, a non-steroidal anti-inflammatory drug, local or regional anaesthesia, neuropathic pain medicines, ice, positioning, mobilisation, wound support and psychological techniques. Non-opioid options still require attention to contraindications, dose ceilings and renal or gastrointestinal risk.

Route selection is a stewardship decision. Oral treatment is generally easier to monitor and continue safely than repeated intravenous boluses when the patient can absorb medicines and does not need rapid titration. Intravenous opioids may be appropriate for severe acute pain, haemodynamic instability or a procedure, but they should come with a transition plan rather than becoming the default ward routine.

Australia’s hospital market includes immediate-release and modified-release products with different strengths, formulations and availability across public and private settings. Brand familiarity can obscure clinically important differences. Prescribers should use generic names, specify the formulation, avoid ambiguous abbreviations and check local electronic prescribing alerts. Pharmacy review is particularly valuable when a patient is opioid-tolerant or taking several centrally acting medicines.

Make Opioid Orders Deliberate

Every opioid order should communicate indication, formulation, dose, route, minimum interval, maximum in 24 hours and review requirements. PRN orders need a clear trigger and should not allow repeated administration without reassessment. If a patient requires frequent breakthrough doses, the answer is a clinical review of the regimen, not an automatic increase in the PRN ceiling.

Dose conversion is a high-risk task. Equianalgesic tables are estimates, and incomplete cross-tolerance means that a calculated new opioid dose may need reduction. Renal and hepatic dysfunction can alter metabolite accumulation, while acute illness changes sensitivity from hour to hour. A second clinician, pharmacist or pain service should check complex conversions, PCA settings and opioid rotations.

Safety monitoring must match risk. Record sedation, respiratory rate, oxygenation, pain function and adverse effects, with greater vigilance after dose increases, parenteral administration or co-prescribing of sedatives. Naloxone protocols should be accessible, and staff should know how to respond to excessive sedation. Constipation prevention, nausea management, falls precautions and delirium observation belong in the original plan rather than being added after complications occur.

Review Use At Every Clinical Handover

Stewardship depends on repeated review. At ward round, ask whether the opioid is still needed, whether the patient can switch to oral treatment, whether non-opioid measures are working and whether the dose can be reduced. A simple “opioid time-out” 24 hours after surgery or acute admission can reveal that pain has improved while the original order remains unchanged.

Nursing documentation can show patterns that a medication chart hides. Frequent PRN requests, delayed relief, sedation after dosing, nocturnal use or refusal because of nausea may point to an unsuitable regimen. Discuss these observations with the patient and bedside team. A patient who asks for medicine often may need better baseline analgesia, while another may need treatment for withdrawal, anxiety, constipation or a new complication.

Transitions are a major risk point. The discharge summary should state the indication, medicine, dose, intended duration, taper instructions and follow-up clinician. Avoid supplying a large quantity “just in case” without a review date. For a patient with persistent pain, arrange a realistic pathway involving the general practitioner, surgeon, pharmacist, pain specialist or addiction service. In Sydney or Brisbane, this may involve several services; in regional Australia, telehealth and early primary-care contact may be essential.

Include Dependence And Harm Reduction

Opioid stewardship is not a judgement about patients who live with chronic pain or opioid dependence. A person receiving methadone or buprenorphine should have this treatment verified and managed carefully, rather than having it stopped without specialist advice. Acute pain may require additional analgesia, with close monitoring and communication between the hospital team and the opioid treatment service.

Ask about overdose risk and provide practical education. Patients and carers should understand sedation, dangerous combinations with alcohol or benzodiazepines, safe storage and when to call emergency services. Take-home naloxone programs operate in Australia, with access varying by state, pharmacy and local service. Hospitals can use discharge conversations to reduce risk without delaying necessary analgesia.

The legal setting matters. Schedule 8 medicines are governed by state and territory poisons legislation, and requirements for authority, storage, prescribing and supply differ between jurisdictions. A discharge prescription written in Adelaide may face different administrative requirements from one written in Hobart or Darwin. Clinicians should follow their hospital policy, consult pharmacy and check current state rules rather than relying on memory.

Turn Principles Into Ward Systems

Individual vigilance is important, but reliable systems make safer prescribing easier. A ward protocol can require an indication, functional goal, sedation-risk screen, bowel regimen, PRN maximum, review date and discharge intention. Electronic prescribing can support this with duplicate-opioid warnings, dose-range alerts and prompts when a patient has received several rescue doses.

Education should include doctors, nurses, pharmacists, allied health professionals and junior staff. Short case-based teaching is often more effective than a lengthy policy: compare a patient after laparoscopic surgery, an older adult with fractured neck of femur and a person maintained on buprenorphine. Each case can test assessment, multimodal options, monitoring, escalation and discharge communication.

Measure process and patient outcomes together. Useful indicators include opioid doses per admission, use of intravenous opioids, naloxone administration, constipation treatment, medication discrepancies and discharge supply duration. Balance these with pain-related function, patient-reported relief, readmission, falls, respiratory events and access to adequate analgesia. A reduction in opioid use is not a success if untreated pain or delayed mobilisation increases.

The most useful next step is to audit ten recent inpatient opioid charts for indication, functional goal, PRN limits, monitoring, bowel care and discharge instructions, then use the findings to create one standard ward order set.